Inflammation-oriented montmorillonite adjuvant enhanced oral delivery of anti-TNF-α nanobody against inflammatory bowel disease
Proceedings of the National Academy of Sciences · 10.09.2024 · 121 (37)
DOI: 10.1073/pnas.2320482121 ↗Kurz gefasst
Fachartikel in der Zeitschrift Proceedings of the National Academy of Sciences, online erschienen am 03.09.2024. Verfasst von Baolian Huang und 9 weiteren Autor:innen. Beteiligte Einrichtung: School of Biopharmacy, China Pharmaceutical University, Nanjing 211198, People's Republic of China. Hauptthemen laut MEDLINE: Bentonite, Tumor Necrosis Factor-alpha, Gastrointestinal Microbiome. Die Arbeit wurde bisher 23-mal zitiert (Crossref) und nennt 56 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: National Natural Science Foundation of China, Natural Science Foundation of Jiangsu Province, Changzhou Municipal Department of Science and Technology.
Abstract (Originalsprache)
Oral delivery of proteins faces challenges due to the harsh conditions of the gastrointestinal (GI) tract, including gastric acid and intestinal enzyme degradation. Permeation enhancers are limited in their ability to deliver proteins with high molecular weight and can potentially cause toxicity by opening tight junctions. To overcome these challenges, we propose the use of montmorillonite (MMT) as an adjuvant that possesses both inflammation-oriented abilities and the ability to regulate gut microbiota. This adjuvant can be used as a universal protein oral delivery technology by fusing with advantageous binding amino acid sequences. We demonstrated that anti-TNF-α nanobody (V II ) can be intercalated into the MMT interlayer space. The carboxylate groups (–COOH) of aspartic acid (D) and glutamic acid (E) interact with the MMT surface through electrostatic interactions with sodium ions (Na + ). The amino groups (NH 2 ) of asparagine (N) and glutamine (Q) are primarily attracted to the MMT layers through hydrogen bonding with oxygen atoms on the surface. This binding mechanism protects V II from degradation and ensures its release in the intestinal tract, as well as retaining biological activity, leading to significantly enhanced therapeutic effects on colitis. Furthermore, V II @MMT increases the abundance of short-chain fatty acids (SCFAs)-producing strains, including Clostridia, Prevotellaceae, Alloprevotella, Oscillospiraceae, Clostridia_vadinBB60_group, and Ruminococcaceae, therefore enhance the production of SCFAs and butyrate, inducing regulatory T cells (Tregs) production to modulate local and systemic immune homeostasis. Overall, the MMT adjuvant provides a promising universal strategy for protein oral delivery by rational designed protein.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- School of Biopharmacy, China Pharmaceutical University, Nanjing 211198, People's Republic of China.
- The State Key Laboratory of Pharmaceutical Biotechnology, College of Life Sciences, Nanjing University, Nanjing, People's Republic of China.
- Changzhou High-Tech Research Institute of Nanjing University and Jiangsu TargetPharma Laboratories Inc., Changzhou 213164, People's Republic of China.
ORCID-Profile: Zhiting Cao
Förderung
- National Natural Science Foundation of China
- Natural Science Foundation of Jiangsu Province
- Changzhou Municipal Department of Science and Technology
Zitieren
APA
Huang, B., Yin, T., Fu, S., Liu, L., Yang, C., Zhou, L., Liu, X., Zhuang, H., Cao, Z., & Hua, Z. (2024). Inflammation-oriented montmorillonite adjuvant enhanced oral delivery of anti-TNF-α nanobody against inflammatory bowel disease. Proceedings of the National Academy of Sciences, 121(37). https://doi.org/10.1073/pnas.2320482121
Vancouver
Huang B, Yin T, Fu S, Liu L, Yang C, Zhou L, et al. Inflammation-oriented montmorillonite adjuvant enhanced oral delivery of anti-TNF-α nanobody against inflammatory bowel disease. Proceedings of the National Academy of Sciences. 2024;121(37). doi:10.1073/pnas.2320482121
BibTeX
@article{Huang2024,
author = {Huang, Baolian and Yin, Te and Fu, Shuilian and Liu, Lina and Yang, Chen and Zhou, Lulu and Liu, Xing and Zhuang, Hongqin and Cao, Zhiting and Hua, Zichun},
title = {Inflammation-oriented montmorillonite adjuvant enhanced oral delivery of anti-TNF-α nanobody against inflammatory bowel disease},
journal = {Proceedings of the National Academy of Sciences},
year = {2024},
volume = {121},
number = {37},
doi = {10.1073/pnas.2320482121}
}
EUVIMED